EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan

Fadwa Benkessou, Ibrahim El-Serafi iD, Rui He, Yikai Yin iD, Limei Ma, Xiaoli Li, Ahmed T El-Serafi iD, Ylva Terelius iD, Tayfun Gungör iD, Manuchehr Abedi-Valugerdi iD, Tingting Wang, Weiyi Zheng und 5 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Fadwa Benkessou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Acetamides, Busulfan. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N,N‐dimethylacetamide (DMA) is an organic solvent, used in busulphan, iv‐formulation, (Busulfex). DMA is metabolized primarily to N‐methylacetamide (MMA) via CYP2E1. In the present study, we investigated the pharmacokinetics and toxicity of DMA and MMA in patients, mice and cell lines. In pediatric patients (6 months to 18 years) undergoing hematopoietic stem cell transplantation, the pharmacokinetics of DMA and MMA were followed during the 4‐days Busulfex conditioning (3.2–4 mg/kg, b.i.d). No accumulation of DMA was found; however, a significant increase in clearance and a significant decrease ( p < 0.005) in half‐lives by the end of treatment were observed which might indicate CYP2E1 autoinduction. Furthermore, continuous increases in plasma concentration of MMA were observed during treatment and a terminal half‐life of 15.2 ± 1.7 h was detected. Moreover, ALT was significantly ( p = 0.04) increased in > 61% of the patients after conditioning. Additionally, mice were treated with either dimethyl sulfoxide (DMSO), DMA, busulphan in DMSO, Busulfex or saline for 4 days. DMA‐treated mice showed elevated ALT and AST values. Interestingly, Busulfex administration did not alter mice liver enzymes. Busulphan in DMA showed higher cytotoxicity compared to busulphan in DMSO in HepG‐2, Huh‐7 and HL‐60 cells. The combination Bu‐DMA‐MMA exhibited increased cytotoxicity in a concentration‐dependent manner. In conclusion, Busulfex administration to pediatric patients resulted in an accumulation of MMA during the 4‐days treatment. Busulfex is less toxic compared to Bu dissolved in DMA. MMA addition to Bu in DMA showed higher cytotoxicity. Therefore, MMA with a relatively long half‐life may induce hepatotoxicity and/or interaction with subsequently administered drugs; thus further investigations are urgently warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetamidesBusulfanHumansChildAnimalsAdolescentChild, PreschoolMiceMaleFemaleInfantHematopoietic Stem Cell TransplantationHalf-LifeDimethyl SulfoxideAdministration, Intravenous

Stichwörter der Autor:innen

BusulphanDMAMMAhepatotoxicitypediatric patients

Substanzen

AcetamidesdimethylacetamideBusulfanDimethyl Sulfoxide

Autor:innen und Institutionen

  • Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Clinical Research Center and Center of Allogeneic Stem Cell Transplantation, Karolinska University Hospital-Huddinge, Stockholm, Sweden.
  • Basic Medical Sciences Department, College of Medicine, Ajman University, Ajman, UAE.
  • Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing, China.
  • Chongqing Key Laboratory of Drug Metabolism, Chongqing, China.
  • The Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden.

ORCID-Profile: Ibrahim El-Serafi, Yikai Yin, Ahmed T El-Serafi, Ylva Terelius, Tayfun Gungör, Manuchehr Abedi-Valugerdi, Massoud Vosough, Ying Zhao, Moustapha Hassan

Zitieren

APA

Benkessou, F., El-Serafi, I., He, R., Yin, Y., Ma, L., Li, X., El-Serafi, A. T., Terelius, Y., Gungör, T., Abedi-Valugerdi, M., Wang, T., Zheng, W., Yu, C., Zhou, W., Vosough, M., Zhao, Y., & Hassan, M. (2025). Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan. Clinical and Translational Science. https://doi.org/10.1111/cts.70433

Vancouver

Benkessou F, El-Serafi I, He R, Yin Y, Ma L, Li X, et al. Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan. Clinical and Translational Science. 2025. doi:10.1111/cts.70433

BibTeX
@article{Benkessou2025,
  author = {Benkessou, Fadwa and El-Serafi, Ibrahim and He, Rui and Yin, Yikai and Ma, Limei and Li, Xiaoli and El-Serafi, Ahmed T and Terelius, Ylva and Gungör, Tayfun and Abedi-Valugerdi, Manuchehr and Wang, Tingting and Zheng, Weiyi and Yu, Chao and Zhou, Weiying and Vosough, Massoud and Zhao, Ying and Hassan, Moustapha},
  title = {Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70433}
}
Kostenlos starten →